Search

Your search keyword '"Inwards, David"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Inwards, David" Remove constraint Author: "Inwards, David" Publisher american society of hematology Remove constraint Publisher: american society of hematology
135 results on '"Inwards, David"'

Search Results

1. Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma

2. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

3. Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

4. Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

5. Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

6. Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

7. Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

8. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

11. Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

13. Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study

14. Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant

15. Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

16. Central Nervous System Involvement By Mantle Cell Lymphoma

17. Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

18. Immunologic Autograft Engineering: 13 Years Follow-up

19. PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

21. Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E

22. Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study

23. Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

24. Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

25. Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL)

26. Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes

27. Central Nervous System Involvement in Peripheral T-Cell Lymphoma

28. Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

29. Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

30. Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era

32. Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

33. Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting

34. Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

35. Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model

36. Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

37. Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia

39. Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

41. Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials

42. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution

43. Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

44. Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy

45. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

46. Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

47. Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress

50. Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma

Catalog

Books, media, physical & digital resources